SEC filings and other documents

Raised 2026 revenue guidance and late-stage pipeline set up multiple 2027 launches.

Strong revenue and profit growth, with key late-stage data readouts expected in late 2026.

Q1 2026 delivered 25% revenue growth, strong product sales, and accelerated late-stage pipeline progress.

Pivotal readouts in 2026 position three late-stage assets for strong growth and market expansion.

Pivotal 2026 trial readouts set up blockbuster launches for three late-stage oncology assets.

EPKINLY leads near-term growth as new oncology launches and disciplined financials shape future revenue.

Diversified portfolio and late-stage pipeline position for strong growth and multiple 2027 launches.

2026 will be a catalyst-rich year, driving growth with pivotal data and multiple launches ahead.

2025 revenue rose 19% to $3.7B, driven by strong proprietary medicine growth and pipeline expansion.

Epcoritamab + R² redefines FL care, driving regulatory, clinical, and commercial momentum.

Late-stage oncology assets and the Merus deal drive growth, with major launches expected by 2027.

Major late-stage oncology assets advance toward 2027 launches, driving future growth.

Strong revenue and profit growth, pipeline progress, and Merus acquisition drive outlook.

$8B acquisition adds PETO, a breakthrough therapy, to drive growth and diversify revenue.

Late-stage oncology assets deliver strong results and set up for major growth through 2026.

Late-stage pipeline progress, strong sales, and global expansion drive future growth.